article thumbnail

Drug discovery hotspots: What is the secret to Switzerland’s success? (p1)

Drug Discovery World

Mazzetti and Schneider continue: “The transfer of technologies from the lab to the market, especially in the field of life sciences is no longer purely via IP out licensing, but rather via start-up M&A deals – start-ups being the de-risking vehicle for large corporates, especially in the life sciences and biotherapeutics sector.

Science 147
article thumbnail

Burning Rock Announces an Exclusive in-Licensing of a Risk Stratification Test for Early Stage Lung-Cancer Patients from Oncocyte in China

The Pharma Data

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. 3 Shi JF et al.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How nucleolar stress accelerates aging in mice

Drug Target Review

In 2005, he joined CNIO to lead the Genomic Instability Group where he has been ever since. These compounds were later licensed to the pharmaceutical industry for clinical development. Oscar Fernandez-Capetillo did his PhD in the University of The Basque Country working with mouse models of autoimmunity with Dr Ana Zubiaga.

RNA 63
article thumbnail

Yesse Technologies secures another grant from The Michael J. Fox Foundation to sniff out Parkinson’s disease

The Pharma Data

Yesse Technologies’ core technology, the ORion21 genetic platform, is the product of over 30 years of fundamental research on the molecular biology of the sense of smell and is exclusively licensed from The City University of New York. The Center is recognized from 2005 onwards as a center of excellence for Parkinson’s disease.

Disease 40
article thumbnail

A Roadmap for Introducing Novel Excipients: How to Approach Excipient Qualification with the FDA

The Premier Consulting Blog

Although novel excipients can be a part of any new drug application (NDA) or biologics license application (BLA) development program, they seem to be more common with the 505(b)(2) pathway, since many companies use cutting-edge delivery technologies to solve issues associated with previously approved drugs.

FDA 52
article thumbnail

EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL

The Pharma Data

Eisai submitted a supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway on January 6, 2023. About the Collaboration between Eisai and BioArctic for AD Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments.

article thumbnail

HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-101

The Pharma Data

To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. 2005; 49(3):873-883. HOOKIPA’s non-replicating prophylactic cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation.

Vaccine 52